Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Acute secondary pulmonary hypertension (PH) often leads to dysfunction of the right ventricle
(RV) and can be a significant cause of patient morbidity and mortality. Selective pulmonary
vasodilation with inhaled nitric oxide (INO) has become the treatment of choice for this
condition. The evidence supporting INO safety and efficacy under these circumstances is
sparse, however, and is largely extrapolated from the use of INO in neonatal pulmonary
hypertension. Moreover, the high cost and potential toxicity of INO makes the therapy far
from ideal. Emerging evidence suggests that inhaled aerosolized prostacyclins such as
iloprost may be a favorable alternative therapy.